Jenburkt Pharma is in the business of manufacturing pharmaceutical formulations – in tablets, capsules, ointments etc. Its plant has been approved by 13 countries for distribution. Its R&D focus is on lifestyle diseases including diabetes, inflammatory conditions, pain relief etc. Its objective is to create long term therapies in acute and chronic ailments. The company has reported modest growth in revenues and operating profits in the last five years – reporting about 10cr of operating profits on revenues of 56cr in the last financial year while employing no net debt to finance its operations. The business is subject to heavy regulatory norms. It is dependent on its R&D to create new and better formulations to maintain competitiveness in an ever-evolving pharmaceutical industry. Moreover, it is subject to high competition and pricing pressures in its generics segment.
An Individual Investor's Perspectives On The Indian Financial Markets